News Release 2021
-
- December 27, 2021
- Kyorin Signed Memorandum of Understanding on Co-Promotion of "Lagevrio Capsule 200mg" for COVID-19 Treatment
-
- November 30, 2021
- Launch of "Compact Real Time PCR System GeneSoC® mini"
-
- November 8, 2021
- Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2021) [Japanese Standard]
-
- November 8, 2021
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
-
- August 3, 2021
- Summary of Consolidated Financial Results (August 3,2021) [Japanese Standard]
-
- August 3, 2021
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
-
- May 11, 2021
- Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2021) [Japanese Standard]
-
- May 11, 2021
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 - Supplementary information
-
- May 7, 2021
- The Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2021
-
- April 26, 2021
- MSD and KYORIN Conclude Distribution Agreement of Gefapixant Citrate, a Treatment for Chronic Cough, in Japan
-
- April 21, 2021
- Launch of the Interstitial cystitis "Zymso® Intravesical Solution 50%"
-
- March 31, 2021
- KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
-
- February 18, 2021
- NHI Drug Price Listing and Release of injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
-
- February 4, 2021
- Summary of Consolidated Financial Results (For the Second Quarter Ended December 31, 2020) [Japanese Standard]
-
- February 4, 2021
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
-
- January 29, 2021
- Release of four research reagents for Microfluidic Real-Time PCR System GeneSoC®
-
- January 22, 2021
- Kyorin Pharmaceutical Receives Marketing Approval for the Interstitial cystitis "Zymso® Intravesical Solution 50%"
